TG Therapeutics (NASDAQ:TGTX) Raised to Hold at StockNews.com

StockNews.com upgraded shares of TG Therapeutics (NASDAQ:TGTX) from a sell rating to a hold rating in a research note issued to investors on Tuesday.

Several other brokerages also recently issued reports on TGTX. The Goldman Sachs Group raised their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. raised their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. Finally, HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Stock Up 0.2 %

TG Therapeutics stock opened at $35.19 on Tuesday. The firm has a market cap of $5.48 billion, a price-to-earnings ratio of -351.86 and a beta of 2.30. The firm has a fifty day moving average price of $30.92 and a two-hundred day moving average price of $28.38. TG Therapeutics has a fifty-two week low of $12.93 and a fifty-two week high of $37.58. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. The firm had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, analysts forecast that TG Therapeutics will post 0.08 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Large investors have recently modified their holdings of the stock. Arizona State Retirement System boosted its stake in TG Therapeutics by 0.9% in the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company’s stock valued at $1,283,000 after buying an additional 364 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 371 shares during the period. Summit Investment Advisors Inc. lifted its holdings in shares of TG Therapeutics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company’s stock valued at $440,000 after acquiring an additional 463 shares during the period. Private Advisor Group LLC grew its holdings in shares of TG Therapeutics by 3.9% in the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after purchasing an additional 542 shares during the last quarter. Finally, Brookstone Capital Management grew its holdings in shares of TG Therapeutics by 3.7% in the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 624 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.